Absorption and Digestion Kinetics of Human Metabolites

Sponsor
University of California, Davis (Other)
Overall Status
Completed
CT.gov ID
NCT05017428
Collaborator
(none)
5
1
4
2.8
1.8

Study Details

Study Description

Brief Summary

The purpose of this pilot study is to evaluate the effects oral supplementation with four human metabolites (spermidine, nicotinamide, palmitoylethanolamide (PEA), and oleoylethanolamide(OEA)) at varying doses on the circulating blood levels of these metabolites as well as their immediate effects on plasma functionality and postprandial inflammation. 5 young healthy subjects will participate in a four armed study consisting of a Placebo arm and a Low, Medium, and High Dose arm. Subjects will be given a standardized breakfast along with supplementation with either an escalating dose (Low: 1x, Medium: 2x, High: 3x) of a combination of spermidine, nicotinamide, PEA and OEA or a placebo control and a time course of their blood plasma will be collected after supplementation. Plasma samples will be assessed for their concentration of spermidine, nicotinamide, PEA, and OEA as well as their experimental and clinical functionalities including their anti-inflammatory, antioxidant, and cholesterol efflux abilities on primary human macrophage.

Condition or Disease Intervention/Treatment Phase
  • Dietary Supplement: Spermidine
  • Dietary Supplement: Nicotinamide
  • Dietary Supplement: PEA
  • Dietary Supplement: OEA
  • Dietary Supplement: Wheat Flour
N/A

Study Design

Study Type:
Interventional
Actual Enrollment :
5 participants
Allocation:
Non-Randomized
Intervention Model:
Crossover Assignment
Intervention Model Description:
Participants will take a supplement containing 4 metabolites at escalating doses compared with placebo after a standardized meal and their blood will be drawn at mutliple points throughout a postprandial time course to evaluate markers of inflammation, circulating levels of each metabolite, and plasma functionalities.Participants will take a supplement containing 4 metabolites at escalating doses compared with placebo after a standardized meal and their blood will be drawn at mutliple points throughout a postprandial time course to evaluate markers of inflammation, circulating levels of each metabolite, and plasma functionalities.
Masking:
None (Open Label)
Primary Purpose:
Basic Science
Official Title:
Absorption and Digestion Kinetics of Human Metabolites
Actual Study Start Date :
Apr 8, 2021
Actual Primary Completion Date :
Jul 1, 2021
Actual Study Completion Date :
Jul 1, 2021

Arms and Interventions

Arm Intervention/Treatment
Experimental: Low Dose

The Low Dose arm provides subjects with supplementation with 5mg of spermidine (in the form of 5g of a 0.1% spermidine wheat germ extract), 500mg of nicotinamide, 400mg of palmitoylethanolamide, and 200mg of oleoylethanolamide.

Dietary Supplement: Spermidine
Spermidine in the form of a 0.1% spermidine wheat germ extract
Other Names:
  • Primeadine
  • Dietary Supplement: Nicotinamide
    Nicotinamide given as niacinamide
    Other Names:
  • Jarrow Niacinamide
  • Dietary Supplement: PEA
    Palmitoylethanolamide given at 98% purity
    Other Names:
  • Nootropics Depot PEA
  • Dietary Supplement: OEA
    Oleoylehtanolamide given at 90% purity
    Other Names:
  • Riduzone
  • Experimental: Medium Dose

    The Medium Dose arm provides subjects with supplementation with 10mg of spermidine (in the form of 10g of a 0.1% spermidine wheat germ extract), 750mg of nicotinamide, 800mg of palmitoylethanolamide, and 400mg of oleoylethanolamide.

    Dietary Supplement: Spermidine
    Spermidine in the form of a 0.1% spermidine wheat germ extract
    Other Names:
  • Primeadine
  • Dietary Supplement: Nicotinamide
    Nicotinamide given as niacinamide
    Other Names:
  • Jarrow Niacinamide
  • Dietary Supplement: PEA
    Palmitoylethanolamide given at 98% purity
    Other Names:
  • Nootropics Depot PEA
  • Dietary Supplement: OEA
    Oleoylehtanolamide given at 90% purity
    Other Names:
  • Riduzone
  • Experimental: High Dose

    The Low Dose arm provides subjects with supplementation with 15mg of spermidine (in the form of 15g of a 0.1% spermidine wheat germ extract), 1000mg of nicotinamide, 1200mg of palmitoylethanolamide, and 600mg of oleoylethanolamide.

    Dietary Supplement: Spermidine
    Spermidine in the form of a 0.1% spermidine wheat germ extract
    Other Names:
  • Primeadine
  • Dietary Supplement: Nicotinamide
    Nicotinamide given as niacinamide
    Other Names:
  • Jarrow Niacinamide
  • Dietary Supplement: PEA
    Palmitoylethanolamide given at 98% purity
    Other Names:
  • Nootropics Depot PEA
  • Dietary Supplement: OEA
    Oleoylehtanolamide given at 90% purity
    Other Names:
  • Riduzone
  • Placebo Comparator: Placebo

    In this arm the participants are given supplementation with a placebo control consisting of 15g of wheat flour.

    Dietary Supplement: Wheat Flour
    Wheat flour given as a placebo control

    Outcome Measures

    Primary Outcome Measures

    1. Circulating Plasma Levels of Metabolites [1, 2, and 4 hours after ingestion]

      Quantitative plasma concentrations of spermidine, nicotinamide, pamitoylethanolamide, and oleoylethanolamide (in nmol/L).

    Secondary Outcome Measures

    1. Anti-inflammatory capacity of plasma [1, 2, and 4 hours after ingestion]

      Ex vivo assessment of the effects of subject plasma on the secretion of pro-inflammatory cytokine TNF-alpha (pg/mL) by primary human macrophage

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    20 Years to 40 Years
    Sexes Eligible for Study:
    Male
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:
    • Age: 20-40 years old to constitute a young study population

    • BMI: 19-27 kg/m2 to constitute a normal/healthy weight population

    • Weight: 133lbs or more

    • Subjects must be willing and able to consume a standardized breakfast bar containing cashews and dates (Larabar).

    • Subjects must be willing to consume oral dietary supplement versions of spermidine, 1-methlynicotinamide, palmitoylethanolamide, and oleoylethanolamide.

    • Subjects must be willing and able to undergo blood draws at the UC Davis Ragle Nutrition Center at 0, 1, 2, and 4 hours after supplementation with spermidine, niacinamide, palmitoylethanolamide, and oleoylethanolamide.

    Exclusion Criteria:
    • Smoker

    • Anemia

    • Documented chronic diseases including diabetes, thyroid disease, metabolic syndrome, cancer, autoimmune diseases, or previous cardiovascular events

    • Any inflammatory bowel disease including IBS, Crohn's Disease, Celiac Disease

    • Any allergy or sensitivity to wheat, gluten, or soy products

    • Consumption of >1 alcoholic drink/day

    • Current consumption of any probiotic, prebiotic, or dietary supplements

    • Extreme dietary or exercise patterns

    • Recent weight fluctuations (greater than 10% in the last six months)

    • Regular use of over-the-counter allergy or pain medications (>1/week)

    • Taking prescription lipid medications (e.g. statins) or other supplements known to alter lipoprotein metabolism such as isoflavones.

    • Use of any form of hormonal birth control including oral contraception pills, hormonal IUDs or rings, or hormonal birth control patches

    • Illness such as flu or cold of any kind within the last two weeks

    • Allergy to components of standardized breakfast bar (cashew/dates)

    • Changes to any of the above during the study period.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 University of California Davis Davis California United States 95616

    Sponsors and Collaborators

    • University of California, Davis

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Angela Zivkovic, PhD, Associate Professor, University of California, Davis
    ClinicalTrials.gov Identifier:
    NCT05017428
    Other Study ID Numbers:
    • 1725738
    First Posted:
    Aug 23, 2021
    Last Update Posted:
    Aug 23, 2021
    Last Verified:
    Aug 1, 2021
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Aug 23, 2021